Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Elan offers special dividend to fend off Royalty

03/04/2013 | 01:34pm EDT

DUBLIN/NEW YORK (Reuters) - Irish drugmaker Elan has sweetened the terms on offer to shareholders under a $3.25 billion (2.15 billion pounds) disposal plan to try to stave off an approach for the company from U.S. investment firm Royalty Pharma .

Elan said on Monday it would give shareholders 20 percent of future royalties from multiple sclerosis drug Tysabri, in which it holds a 50 percent interest that it plans to sell to its U.S. partner Biogen Idec (>> Biogen Idec Inc.).

The Irish group had unveiled the restructuring a month ago, saying it would gain flexibility to buy new assets. It has already said it would also return $1 billion to shareholders.

Those plans were put under question when New York-based Royalty made its $6.6 billion approach last week.

Royalty's indicative approach, worth $11 per Elan share, could scupper Elan's plans to spend the rest of the proceeds from the Tysabri deal on a series of acquisitions, effectively reinventing itself as a company.

Despite Elan's rejection, Royalty plans to make its case to some of the drugmaker's largest shareholders later this week.

Elan said on Monday most of its shareholders did not view Royalty's idea as worth consideration.

"We simply don't view the Royalty indication of interest as credible. The vast majority of our investor base simply don't view Royalty's indication as worthy of any discussion," Chief Executive Kelly Martin told Reuters in a telephone interview.

"I wish Royalty well, they can do what they need to do, but we're not in any discussions with them at all on any topic and we don't see any need to have those discussions," Martin said.

The CEO said he was referring to Elan's outside investors and had not discussed the approach with Johnson & Johnson (>> Johnson & Johnson), which owns 18 percent of the group.

Royalty Pharma, which buys royalty streams of patented drugs, is not giving up, however.

"We have approached Elan's Chairman with a possible offer at a cash premium, and we are very serious about our offer," said Pablo Legorreta, chief executive officer of Royalty Pharma, in a written statement Tuesday. "I'm therefore struggling to understand why this offer is, in the words of Kelly Martin, "not credible." We look forward to meeting a number of Elan's large shareholders who have agreed to meet with us later this week."

At least one investor, Larry Feinberg, founder and president of Greenwich, Connecticut-based Oracle Investment Management, backed Martin's plan and has bought 2 million shares of Elan since the Tysabri deal was announced.

"I think Elan is signalling that they are going to be not just a development stage company and that they are really looking for commercial stage businesses," Feinberg, whom Elan has not contacted about the deal, told Reuters.

"I think the Royalty Pharma bid puts a floor on the stock now. The management has to prove that they can create value and I believe they will."

TYSABRI UPSIDE

Elan shares are up more than 10 percent at $11.48 since Royalty made their deal public, a signal that the market believes the New York firm will have to increase its offer.

Martin dismissed Royalty's criticism that Elan's senior management had little experience making acquisitions. He said potential deals the group was looking at included some assets worth more than $1 billion.

The Tysabri deal should close in the coming month or two, Martin said, adding Elan would provide further clarity on its plans in coming days and weeks.

Once the deal closes, the Dublin-based company said shareholders could expect the first of twice-yearly dividend payments on the drug in the fourth quarter of 2013.

In the deal with Biogen, Elan's royalty payments on future Tysabri sales, which rose 8 percent to $1.63 billion in 2012, will be 12 percent for the first year, 18 percent after that, and 25 percent when annual sales rise above $2 billion.

Martin said shareholders would therefore get 5 percent of any income on the drug above $2 billion. Biogen aims to increase patient numbers over time to 100,000 from the 72,700 at the end of last year, a level that would make Tysabri a $2 billion drug.

Using its Tysabri sales and share buyback assumptions, analysts at Berenberg Bank said the dividend equates to $68 million in 2014 and increases to $175 million in 2023.

"This news reduces Royalty's options and, if serious in its intentions, increases the need for a higher formal offer that more fairly reflects Tysabri upside," Berenberg said in a note.

(Editing by David Holmes, Jane Merriman and Andrew Hay)

By Padraic Halpin and Jessica Toonkel

Stocks treated in this article : Biogen Idec Inc., Elan Corporation, plc, Johnson & Johnson

© Reuters 2013
Stocks mentioned in the article
ChangeLast1st jan.
BASE CO., LTD. 1.75% 4935 End-of-day quote.-19.76%
BASE, INC. -3.36% 1525 End-of-day quote.-21.88%
BIOGEN INC. -0.29% 325.4 Delayed Quote.33.28%
ELAN CORPORATION LTD -0.39% 12.71 End-of-day quote.0.00%
JOHNSON & JOHNSON 1.06% 171.79 Delayed Quote.9.16%
ROYALTY PHARMA PLC -0.07% 40.33 Delayed Quote.-19.42%
All news about JOHNSON & JOHNSON
07/23Relaxed Border Restrictions For U.S. Travelers Coming August 9, 2021
AQ
07/23GLOBAL MARKETS LIVE : Intel, HoneyWell, American Express, Visa, Twitter...
07/23JOHNSON & JOHNSON : UBS Adjusts Johnson & Johnson's Price Target to $183 From $1..
MT
07/23ASTRAZENECA : EU On Track To Donate 200 Million COVID-19 Vaccine Doses In 2021
MT
07/22JOHNSON & JOHNSON : Opioid-ravaged West Virginia looks to $26B deal for help
AQ
07/22JOHNSON & JOHNSON : In opioid-ravaged WVa, potential deal raises hopes for help
AQ
07/22JOHNSON & JOHNSON : Genmab Announces Net Sales of DARZALEX (daratumumab) for the..
AQ
07/22JOHNSON & JOHNSON : Covid-19 Vaccines - Current Challenge Is Not Supply but Usin..
AQ
07/21CARDINAL HEALTH : States reach $26B opioid settlement with Johnson & Johnson, 'b..
AQ
07/21JOHNSON & JOHNSON : Strong Q2 from J&J as pandemic-hit sales, profit recover
AQ
More news
Financials (USD)
Sales 2021 94 447 M - -
Net income 2021 22 808 M - -
Net Debt 2021 871 M - -
P/E ratio 2021 20,2x
Yield 2021 2,40%
Capitalization 452 B 452 B -
EV / Sales 2021 4,80x
EV / Sales 2022 4,58x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 171,79 $
Average target price 184,35 $
Spread / Average Target 7,31%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246
ABBVIE INC.10.30%199 548